Zentiva Group, a.s.
Zentiva Group, a.s., headquartered in the Czech Republic, is a prominent player in the pharmaceutical industry, specialising in generic and over-the-counter medicines. Founded in 1998, the company has established a strong presence across Central and Eastern Europe, focusing on delivering high-quality, affordable healthcare solutions. Zentiva's core product offerings include a diverse range of generic pharmaceuticals, which are distinguished by their commitment to quality and accessibility. The company has achieved significant milestones, including expanding its portfolio and enhancing its manufacturing capabilities, positioning itself as a trusted provider in the market. With a dedication to innovation and patient-centric solutions, Zentiva continues to strengthen its market position, contributing to improved health outcomes across the regions it serves.
DitchCarbon Score
How does Zentiva Group, a.s.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Real Estate Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zentiva Group, a.s.'s score of 20 is lower than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Zentiva Group, a.s.'s reported carbon emissions
In 2021, Zentiva Group, a.s. reported significant carbon emissions, totalling approximately 305,480,000 kg CO2e for Scope 1 and about 79,081,000 kg CO2e for Scope 2. The company has set ambitious climate commitments, aiming to achieve carbon neutrality for Scope 1 and Scope 2 emissions by 2030. This commitment is contingent upon advancements in process technology and operational practices. Zentiva has established near-term targets to reduce absolute Scope 1 and Scope 2 greenhouse gas emissions by 63% by 2034, using 2021 as the baseline year. Furthermore, the company has long-term goals to cut these emissions by 90% by 2050. For Scope 3 emissions, Zentiva also targets a 63% reduction by 2034 from a 2024 baseline, with a long-term goal of a 90% reduction by 2050. These targets align with the Science Based Targets initiative (SBTi) and are designed to support the global effort to limit temperature rise to 1.5°C. Zentiva's commitment to net-zero emissions across its entire value chain by 2050 underscores its dedication to sustainability within the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | |
|---|---|
| Scope 1 | 305,480,000 |
| Scope 2 | 79,081,000 |
| Scope 3 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zentiva Group, a.s. is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
